ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy

Permanent lenke
https://hdl.handle.net/10037/13488
DOI
https://doi.org/10.14740/jocmr2653w
Thumbnail
Åpne
article.pdf (504.6Kb)
Publisher's version (PDF)
Dato
2017-01-25
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Nieder, Carsten; Dalhaug, Astrid; Haukland, Ellinor; Mannsåker, Bård; Pawinski, Adam
Sammendrag

Background: The aim of the study was to explore the prognostic impact of different abnormal blood tests and the tumor marker CA 15-3 as well as established parameters such as disease extent and receptor status in patients with bone metastases from breast cancer who received palliative radiotherapy in addition to contemporary systemic treatment.

Methods: This was a retrospective uni- and multivariate analysis of 118 female patients treated in the time period from 2007 to 2014 (median follow-up 28 months).

Results: The median age was 61 years and the median time interval from the initial diagnosis of breast cancer was 57 months (median time interval from metastatic disease to radiotherapy was 7 months). Only 16% of patients had normal serum CA 15-3. HER2 receptor status correlated with CA 15-3. The median survival was 17.6 months (lowest CA 15-3 quartile), 14.7 months (intermediate), and 6.9 months (highest quartile) (P = 0.002). However, multivariate analysis showed that survival was influenced by extent of extra-skeletal metastases, pleural metastases/effusion, lung metastases, estrogen receptor status, serum C-reactive protein, and anemia with need for blood transfusion (all P < 0.05) rather than CA 15-3.

Conclusions: Survival was highly variable. The tumor marker CA 15-3 did not provide independent prognostic information. Nevertheless, the results of simple blood tests contributed to the multivariate prognostic model.

Beskrivelse
Source at https://doi.org/10.14740/jocmr2653w. Accepted manuscript version, licensed CC BY-NC-ND 4.0.
Forlag
Elmer Press
Sitering
Nieder, C., Dalhaug, A., Haukland, E., Mannsåker, B. & Pawinski, A. (2017). Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. Journal of Clinical Medicine Research, 9(3), 183-187. https://doi.org/10.14740/jocmr2653w
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring